블로그

• [FDA, 200616] 키트루다, 고형암 환자 대상 허가 Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high blog.naver.com · 2020.06.30